These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24018545)

  • 21. Atomoxetine in the treatment of attention deficit hyperactivity disorder.
    Kratochvil CJ; Vaughan BS; Daughton JM; Mayfield-Jorgensen ML; Burke WJ
    Expert Rev Neurother; 2004 Jul; 4(4):601-11. PubMed ID: 15853579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does atomoxetine improve executive function, inhibitory control, and hyperactivity? Results from a placebo-controlled trial using quantitative measurement technology.
    Wehmeier PM; Schacht A; Ulberstad F; Lehmann M; Schneider-Fresenius C; Lehmkuhl G; Dittmann RW; Banaschewski T
    J Clin Psychopharmacol; 2012 Oct; 32(5):653-60. PubMed ID: 22926599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.
    Wilens TE; Adler LA; Weiss MD; Michelson D; Ramsey JL; Moore RJ; Renard D; Brady KT; Trzepacz PT; Schuh LM; Ahrbecker LM; Levine LR;
    Drug Alcohol Depend; 2008 Jul; 96(1-2):145-54. PubMed ID: 18403134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of atomoxetine on Tanner stage sexual development in children and adolescents with attention deficit/hyperactivity disorder: 18-month results from a double-blind, placebo-controlled trial.
    Trzepacz PT; Spencer TJ; Zhang S; Bangs ME; Witte MM; Desaiah D
    Curr Med Res Opin; 2011; 27 Suppl 2():45-52. PubMed ID: 21973230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics of placebo responders in pediatric clinical trials of attention-deficit/hyperactivity disorder.
    Newcorn JH; Sutton VK; Zhang S; Wilens T; Kratochvil C; Emslie GJ; D'souza DN; Schuh LM; Allen AJ
    J Am Acad Child Adolesc Psychiatry; 2009 Dec; 48(12):1165-72. PubMed ID: 19858759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.
    ; Bangs ME; Emslie GJ; Spencer TJ; Ramsey JL; Carlson C; Bartky EJ; Busner J; Duesenberg DA; Harshawat P; Kaplan SL; Quintana H; Allen AJ; Sumner CR
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):407-20. PubMed ID: 17822337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Electroencephalographic study of children with attention deficit hyperactivity disorder before and after treatment with strattera].
    Nikishina IS; Chutko LS; Surushina SIu; Iakovenko EA; Kropotov IuD
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(12):60-2. PubMed ID: 19253469
    [No Abstract]   [Full Text] [Related]  

  • 28. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atomoxetine for attention deficit hyperactivity disorder in mental retardation.
    Fernández-Jaén A; Fernández-Mayoralas DM; Calleja Pérez B; Muñoz Jareño N; Campos Díaz Mdel R
    Pediatr Neurol; 2010 Nov; 43(5):341-7. PubMed ID: 20933178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning.
    Brown RT; Perwien A; Faries DE; Kratochvil CJ; Vaughan BS
    Clin Pediatr (Phila); 2006 Nov; 45(9):819-27. PubMed ID: 17041169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
    Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
    Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Atomoxetine for the treatment of attention-deficit/hyperactivity disorder].
    Davids E; Gastpar M
    Fortschr Neurol Psychiatr; 2004 Oct; 72(10):586-91. PubMed ID: 15472782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD.
    Saylor K; Williams DW; Schuh KJ; Wietecha L; Greenbaum M
    Curr Med Res Opin; 2010 Sep; 26(9):2087-95. PubMed ID: 20642391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Autism and attention deficit hyperactivity disorder: pharmacological intervention].
    Fernández-Jaén A; Martín Fernández-Mayoralas D; Fernández-Perrone AL; Calleja-Pérez B; Muñoz-Jareño N; López-Arribas S
    Rev Neurol; 2013 Sep; 57 Suppl 1():S205-10. PubMed ID: 23897149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial.
    Arnold LE; Aman MG; Cook AM; Witwer AN; Hall KL; Thompson S; Ramadan Y
    J Am Acad Child Adolesc Psychiatry; 2006 Oct; 45(10):1196-1205. PubMed ID: 17003665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD.
    Polzer J; Bangs ME; Zhang S; Dellva MA; Tauscher-Wisniewski S; Acharya N; Watson SB; Allen AJ; Wilens TE
    Biol Psychiatry; 2007 Mar; 61(5):713-9. PubMed ID: 16996485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effectiveness of strattera in children and adolescents with attention deficit hyperactivity disorder].
    Vakula IN; Vasianina IuSh; Gorbunova ZKh; Nikiforova EIu; Ponomarenko EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(8):42-4. PubMed ID: 19738568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome.
    Spencer TJ; Sallee FR; Gilbert DL; Dunn DW; McCracken JT; Coffey BJ; Budman CL; Ricardi RK; Leonard HL; Allen AJ; Milton DR; Feldman PD; Kelsey DK; Geller DA; Linder SL; Lewis DW; Winner PK; Kurlan RM; Mintz M
    J Atten Disord; 2008 Jan; 11(4):470-81. PubMed ID: 17934184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit/hyperactivity disorder.
    Takahashi M; Takita Y; Goto T; Ichikawa H; Saito K; Matsumoto H; Tanaka Y
    Psychiatry Clin Neurosci; 2011 Feb; 65(1):55-63. PubMed ID: 21265936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.